Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Liquidia Technologies, retaining the price target of $54.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the promising developments at Liquidia Technologies. The company has presented encouraging long-term data from its ASCENT study with Yutrepia, showing improvements in patient outcomes over a 24-week period. This data supports the differentiated and superior product profile of Yutrepia, which is expected to drive a strong market launch.
Additionally, Liquidia’s new data and updates on L606, a next-generation nebulized treprostinil, demonstrate its potential to expand the company’s treprostinil franchise. The 48-week safety study of L606 revealed no severe adverse events and stable functional outcomes, suggesting it could offer higher tolerated doses with less frequent administration. The planned global Phase 3 trial, Re-Spire, further underscores Liquidia’s commitment to advancing its pipeline, making it a compelling investment opportunity.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LQDA in relation to earlier this year.